Clinical Trial

Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders

Study acronym: SPIRIT_1
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).
Trial Details
NCT Number NCT07651917
Lead Sponsor University of Zurich
Collaborators: National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Conditions Neurocognition
Enrollment 50 participants
Start Date 2026-06-18
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16